How do you treat at the speed of cancer?

The answers are in our blood

Guardant360® CDx is the first FDA-approved comprehensive liquid biopsy for all advanced solid tumors

Highlights

Article

Precise and Rapid Advanced Cancer Treatment Selection

Read more

Guardant360 CDx gene list

Inform treatment decisions across all solid tumors

View gene list

Article

A New Standard of Care

Read more

Get essential answers before initiating treatment.

Learn how liquid biopsy has changed the treatment paradigm.

Find out more

play button

Dr. Nicolas Rohs |
Thoracic Medical Oncologist Mount Sinai Medical Center

Guardant360 CDx is:

First FDA-approved comprehensive liquid biopsy

Complete genomic results in 7 days

Medicare-covered for all solid tumors, regardless of tissue availability

Seamlessly integrate Guardant360 CDx into your practice.

Comprehensive support and educational resources for you and your patients.

Find out more

Featured Publications

Key Findings

  • In the NSCLC cohort, 32.2% (19 patients) had a confirmed objective response (complete or partial response) and 88.1% (52 patients) had disease control (objective response or stable disease).
  • The median progression-free survival was 6.3 months.

Learn More

Key Findings24

  • Concordance between Guardant360 and tissue testing was greater than 90% for the four biomarkers with FDA-approved therapies
  • Guideline-recommended biomarker testing was completed for 95% of patients with Guardant360 vs. 31% with standard-of-care tissue testing
  • Turnaround time was ~1 week faster with Guardant360 vs. SOC tissue testing

Learn More

Key Findings25

  • 44% of eligible patients were unable to get complete genomic results from tissue biopsy
  • 2x as many patients had targetable alterations detected by Guardant360 and tissue testing (n=82) versus tissue testing alone (n=47)
  • 86% of patients had a response or stable disease based on RECIST criteria

Learn More

Key Findings19

  • Guardant360 detects guideline-complete alterations in advanced NSCLC patients, including MET exon 14 skipping alterations
  • ORR and DCR equivalent in Guardant360 and tissue biopsy groups in the VISION trial MET exon 14 skipping NSCLC cohort

Learn More

Key Findings26

  • The demands on tissue specimens from diagnostic stains and PD-L1 testing may leave little remaining for genomic profiling
  • Gaps in genomic biomarker testing can be overcome with new technologies

Learn More

Key Findings27

  • Comprehensive ctDNA testing can effectively guide therapy selection
  • Response rates to therapy selected based on Guardant360 results were consistent with those in tissue-based targeted therapy studies

Learn More